Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-discharge antithrombotic strategies in patients with COVID-19
2021-002298-25Phase 3Terminated
- Sponsor
- FIBHULP
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by FIBHULP. Primary endpoint: Composite thromboembolic and mortality endpoint. Started Jul 2021; status: terminated.
02
Drugs
apixaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002298-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002298-25.